Combination therapy for advanced digestive system neuroendocrine cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of drugs as the first treatment for people with advanced neuroendocrine cancer of the digestive system that has spread. It aims to see if the combination can shrink tumors and help people live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with neuroendocrine cancer of the digestive system that has spread to other parts of the body.
- You have not had any previous treatment for this cancer, or if you had adjuvant therapy, it ended more than 6 months ago.
- You have measurable tumors that can be assessed by imaging scans.
- You are in good general health, with a performance status of 0 or 1 (able to carry out daily activities).
- You have adequate organ and bone marrow function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (an immunotherapy, a targeted therapy, and a chemotherapy) for advanced neuroendocrine carcinoma. It is designed for people whose cancer has progressed after at least one prior treatment, and aims to see if this combination can help control the cancer.
This trial tests a new combination of two immunotherapy drugs (zimberelimab and domvanalimab) added to a standard chemotherapy regimen called FOLFIRI, to see if it works better than FOLFIRI alone for a rare and aggressive type of cancer called neuroendocrine carcinoma. It is for people whose cancer has progressed after a first-line chemotherapy, and aims to help slow the cancer's growth.
This trial tests a chemotherapy drug called irinotecan liposomes for people with high-grade neuroendocrine tumors or neuroendocrine cancers of the digestive system. The goal is to see if this treatment can help shrink or control the tumors.
This study looks at whether chemotherapy given before surgery improves how long patients live without the cancer coming back. It’s aimed at people with localized, poorly differentiated digestive neuroendocrine carcinoma with a higher growth rate marker.
This trial tests a new form of the chemotherapy drug irinotecan (called liposomal irinotecan) in people whose advanced neuroendocrine carcinoma has stopped responding to standard first-line treatment. The goal is to see if this special formulation can help slow or shrink the cancer.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
Hear when a new Neuroendocrine Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.